Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
CRISPR Therapeutics (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out. Still, investing in biotech companies isn't for the faint of heart, and even a slightly less risky contender like CRISPR Therapeutics could have a few pitfalls lurking. Let's take a look at where this biotech is going, and whether it could be a good fit for your portfolio this year. This revenue ramp-up will be dizzyingly quick In the near term, there's a very clear path for this company to massively increase the size of its top line, and the medium term also offers a high probability of earnings growth. Here's why. CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell diseas
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Ark Next Generation Internet ETF vs. Ark Innovation ETF: Which Is Best for You? [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres [Seeking Alpha]Seeking Alpha
- Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear? [Yahoo! Finance]Yahoo! Finance
- Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 8/12/24 - Form 4
- 8/5/24 - Form S-3ASR
- 8/5/24 - Form S-8
- CRSP's page on the SEC website